All In Biotech

BLA 020986 · Novo Nordisk INC

Novolog Penfill

Insulin Aspart Recombinant · Subcutaneous · Insulin Analog

Novel

Last checked: Nov 20, 2026Latest source record: Feb 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Jun 7, 2000

Approved uses

n/a

Original approval plus efficacy supplements

Registered trials

8

0 Phase 3, 0 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

FDA's data service is rate-limiting requests. Try again in a minute. The numbers below may be missing or incomplete.

No approvals could be loaded from Drugs@FDA just now.

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Aspart Recombinant" as an intervention, any sponsor and status, largest first.

All 8 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
FDA's data service is rate-limiting requests. Try again in a minute. The numbers below may be missing or incomplete.

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Novolog (Insulin Aspart)

2024 spending

$85.5M

Beneficiaries

111,329

370,385 claims

Per beneficiary

$768

$6.98 per unit

View as table
YearSpending
2020$586,977,753
2021$546,397,744
2022$522,823,749
2023$518,394,273
2024$85,508,606

Part D: Novolog Flexpen (Insulin Aspart)

2024 spending

$319M

Beneficiaries

479,549

1,483,591 claims

Per beneficiary

$665

$8.90 per unit

View as table
YearSpending
2020$1,844,084,368
2021$1,817,675,039
2022$1,839,750,389
2023$1,875,605,627
2024$318,913,549

Part D: Novolog Penfill (Insulin Aspart)

2024 spending

$2.2M

Beneficiaries

3,863

9,358 claims

Per beneficiary

$578

$8.60 per unit

View as table
YearSpending
2020$8,204,522
2021$9,825,961
2022$11,977,767
2023$13,098,434
2024$2,231,024

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Novo Nordisk · Also marketed as Novolog Flextouch, Novolog Flexpen, Novolog, Novolog Innolet

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.